In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...

In this webinar, you’ll learn about GLP-1 agonists that can help with obesity treatment, common side effects of these drugs, misunderstandings about their use, and more. About the expert ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

The success surrounding the medications for obesity and diabetes has sparked research into whether they could also be an ...

Current GLP-1-based obesity medications are effective ... a next-generation anti-obesity drug (LA-GLP/GIP/GCG), and semaglutide. The combination therapy demonstrated a substantial reduction ...

TUESDAY, Nov. 5, 2024 (HealthDay News) -- Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow ...

Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found. Only 13 states currently allow Medicaid to cover treatment of obesity using ...